Novel diazabicycloalkane delta opioid agonists

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• Selective delta (δ) opioid agonists are valuable therapeutic targets.
• The diazatricyclodecane scaffold has yielded potent δ opioid agonists like SNC80.
• Conformationally constrained analogues are sought to improve pharmacological profiles.

Purpose of the Study:

• To investigate diazabicycloalkane cores as novel scaffolds for δ opioid agonists.
• To develop conformationally constrained analogues of known δ opioid agonists.
• To identify compounds with improved affinity and selectivity for the δ opioid receptor.

Main Methods:

• Synthesis of novel diazabicycloalkane derivatives.
• Biological assaying of synthesized compounds for δ opioid receptor activity.
• Evaluation of binding affinity and selectivity of novel compounds.

Main Results:

• All synthesized novel compounds (3-7) exhibited δ agonism.
• Compounds demonstrated remarkable affinity for δ opioid receptors.
• The 3,8-diazabicyclo[3.2.1]octane derivative (compound 4) showed superior δ affinity and selectivity over SNC80.

Conclusions:

• Diazabicycloalkane cores represent promising scaffolds for developing novel δ opioid agonists.
• The 3,8-diazabicyclo[3.2.1]octane motif is particularly effective in enhancing δ opioid receptor affinity and selectivity.
• These findings pave the way for new therapeutics targeting the δ opioid system.